Laboratory of Behavioral Neuroscience, National Institute of Mental Health, Bethesda, MD 20892-3730, USA.
Neuropharmacology. 2013 May;68:210-22. doi: 10.1016/j.neuropharm.2012.07.042. Epub 2012 Aug 8.
Translational research is needed to discover pharmacological targets and treatments for the diagnostic behavioral domains of autism spectrum disorders. Animal models with phenotypic relevance to diagnostic criteria offer clear experimental strategies to test the efficacy and safety of novel treatments. Antagonists of mGluR5 receptors are in clinical trials for Fragile X syndrome and under investigation for the treatment of autism spectrum disorders. However, in preclinical studies of mGluR5 compounds tested in our laboratory and others, increased locomotion following mGluR5 modulation has been observed. Understanding the influence of general activity on sociability and repetitive behaviors will increase the accuracy of interpretations of positive outcomes measured from pharmacological treatment that produces locomotor activating or sedating effects. In the present studies, dose-response curves for d-amphetamine (AMPH)-induced hyperlocomotion were similar in standard B6 mice and in the BTBR mouse model of autism. AMPH produced significant, robust reductions in the high level of repetitive self-grooming that characterizes BTBR, and also reduced the low baseline grooming in B6, indicating that AMPH-induced hyperlocomotion competes with time spent engaged in self-grooming. We then tested AMPH in B6 and BTBR on the 3-chambered social approach task. One component of sociability, the time spent in the chamber with the novel mouse, in B6 mice was reduced, while the sniffing time component of sociability in BTBR mice was enhanced. This finding replicated across multiple cohorts treated with AMPH and saline vehicle. In-depth analysis revealed that AMPH increased the number and decreased the duration of sniffing bouts in BTBR, suggesting BTBR treated with AMPH mostly engaged in brief sniffs rather than true social interactions with the novel mouse during the social approach task. Our data suggest that compounds with stimulant properties may have some direct benefits on reducing repetitive behaviors in autism spectrum disorders, particularly in the subset of autistic individuals with hyperactivity. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.
需要进行转化研究,以发现用于自闭症谱系障碍诊断行为领域的药理学靶点和治疗方法。具有与诊断标准相关表型的动物模型为测试新型治疗方法的疗效和安全性提供了明确的实验策略。mGluR5 受体拮抗剂正在脆性 X 综合征的临床试验中进行测试,并正在研究用于治疗自闭症谱系障碍。然而,在我们实验室和其他实验室测试的 mGluR5 化合物的临床前研究中,观察到 mGluR5 调节后运动增加。了解一般活动对社交能力和重复性行为的影响将提高对具有运动激活或镇静作用的药物治疗产生的阳性结果的解释的准确性。在本研究中,d-苯丙胺(AMPH)诱导的过度运动的剂量反应曲线在标准 B6 小鼠和自闭症的 BTBR 小鼠模型中相似。AMPH 显著减少了 BTBR 特征性的高水平重复自我梳理,并且还减少了 B6 中的基线梳理,表明 AMPH 诱导的过度运动与参与自我梳理的时间竞争。然后,我们在 B6 和 BTBR 上测试了 AMPH 在三腔社交接近任务中的作用。在 B6 小鼠中,社交的一个组成部分,即与新小鼠在同一室中度过的时间减少了,而 BTBR 小鼠的社交嗅探时间成分增强了。这一发现通过用 AMPH 和盐水载体治疗的多个队列得到了复制。深入分析表明,AMPH 增加了 BTBR 嗅探回合的数量并减少了其持续时间,这表明 BTBR 用 AMPH 治疗的大多数嗅探是短暂的嗅探,而不是在社交接近任务中与新小鼠进行真正的社交互动。我们的数据表明,具有兴奋剂特性的化合物可能对减少自闭症谱系障碍中的重复性行为具有一些直接的益处,特别是在具有多动性的自闭症个体亚组中。本文是题为“神经发育障碍”的特刊的一部分。